Devyser Diagnostics Q2: An unnoticed high-quality growth case - Redeye

Redeye is encouraged by the continuing geographical expansion, and that first sales have come from the Thermo Fischer deal (in Q3), but we make some downward adjustments to our financial forecasts. We reiterate our take on Devyser’s share offering attractive entry points for a relatively de-risked growth case, though somewhat lowering our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/939310/devyser-diagnostics-q2-an-unnoticed-high-quality-growth-case?utm_source=finwire&utm_medium=RSS